Shensong Yangxin Capsule in the Treatment of Heart Failure Complicated With Ventricular Premature Beat
Shensong Yangxin Capsule in the Treatment of Mild to Moderate Systolic Heart Failure Complicated With Ventricular Premature Beat: A Randomize, Double Blind, Placebo-controlled Multicenter Clinical Trial
Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital
This PHASE4 trial investigates Heart Failure and Ventricular Premature Complex and is currently ongoing. Chinese Academy of Medical Sciences, Fuwai Hospital leads this study, which shows 5 recorded versions since 2012 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE4
First recorded
Sep 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Chinese Academy of Medical Sciences, Fuwai Hospital
- Cong-xin Huang
- Fudan University
- Nanjing Medical University
- Shanghai Changzheng Hospital
- Third Military Medical University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Chengdu, China , Chongqing, China , Enshi, China , Jinan, China , Jingzhou, China , Nanjing, China , Nanning, China , Shanghai, China , Shenyang, China and 6 more locations